First-in-human gene editing for lipid lowering: the initial results.
作者信息
Tual-Chalot Simon, Stellos Konstantinos
机构信息
Biosciences Institute, Vascular Biology and Medicine Theme, Faculty of Medical Sciences, Newcastle University, Centre for Life, Newcastle Upon Tyne NE1 3BZ, UK.
Department of Cardiovascular Research, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Ludolf-Krehl-Straße 13-17, D-68167 Mannheim, Germany.
出版信息
Cardiovasc Res. 2024 Mar 30;120(4):e5-e8. doi: 10.1093/cvr/cvae037.
Abstract
摘要
相似文献
1
First-in-human gene editing for lipid lowering: the initial results.首次人体基因编辑降血脂：初步结果
Cardiovasc Res. 2024 Mar 30;120(4):e5-e8. doi: 10.1093/cvr/cvae037.
2
Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂降低脂蛋白(a)水平并降低心血管疾病风险
Atherosclerosis. 2022 Nov;361:30-31. doi: 10.1016/j.atherosclerosis.2022.10.010. Epub 2022 Oct 21.
3
Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.前蛋白转化酶枯草溶菌素9抑制剂（PCSK9i）在动脉粥样硬化性心血管疾病中的应用：欢迎真实世界数据
J Cardiovasc Pharmacol. 2023 May 1;81(5):336-338. doi: 10.1097/FJC.0000000000001411.
4
Lipid-lowering therapies in peripheral artery disease: A review.外周动脉疾病的降脂治疗：综述。
Vasc Med. 2021 Feb;26(1):71-80. doi: 10.1177/1358863X20957091. Epub 2020 Oct 19.
5
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.前蛋白转化酶枯草溶菌素/胰凝乳蛋白酶 9 抑制剂和小干扰 RNA 治疗降低心血管风险：系统评价和荟萃分析。
PLoS One. 2023 Dec 6;18(12):e0295359. doi: 10.1371/journal.pone.0295359. eCollection 2023.
6
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.系统评价和网络荟萃分析：依洛尤单抗与其他疗法在治疗高血脂症患者血脂水平方面的疗效比较。
J Am Heart Assoc. 2017 Oct 2;6(10):e005367. doi: 10.1161/JAHA.116.005367.
7
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南：基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
8
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.在PCSK9抑制剂时代，我们是否需要新型降脂药物？最新进展。
Kardiol Pol. 2022;80(7-8):741-749. doi: 10.33963/KP.a2022.0117. Epub 2022 May 6.
9
Effect of PCSK9 Inhibition on the Plasma Proteome: A SPIRE SubStudy.前蛋白转化酶枯草溶菌素9（PCSK9）抑制对血浆蛋白质组的影响：SPIRE子研究
Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1595-1597. doi: 10.1161/ATVBAHA.123.319272. Epub 2023 Jun 15.
10
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.对动脉粥样硬化性心血管疾病极高危患者强化降脂治疗（LLT）的模拟。
J Clin Lipidol. 2022 Nov-Dec;16(6):901-905. doi: 10.1016/j.jacl.2022.10.001. Epub 2022 Oct 14.
本文引用的文献
1
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing.靶向 PCSK9 的新方法：小干扰核糖核酸和基因组编辑。
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1081-1092. doi: 10.1161/ATVBAHA.122.317963. Epub 2023 Jun 1.
2
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.降脂新药 inclisiran 在高心血管风险和高 LDL 胆固醇患者中的长期疗效和安全性（ORION-3）：ORION-1 试验 4 年开放标签扩展的结果。
Lancet Diabetes Endocrinol. 2023 Feb;11(2):109-119. doi: 10.1016/S2213-8587(22)00353-9. Epub 2023 Jan 5.
3
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.PCSK9 抑制剂对残余胆固醇和脂质残余风险的影响：LIPID-REAL 登记研究。
Eur J Clin Invest. 2022 Dec;52(12):e13863. doi: 10.1111/eci.13863. Epub 2022 Sep 5.
4
Remnant cholesterol and atherosclerotic disease in high cardiovascular risk patients. Beyond LDL cholesterol and hypolipidemic treatment.残余胆固醇与心血管高危患者的动脉粥样硬化性疾病。超越 LDL 胆固醇和降脂治疗。
Hellenic J Cardiol. 2022 Jul-Aug;66:26-31. doi: 10.1016/j.hjc.2022.05.011. Epub 2022 Jun 4.
5
Moving toward genome-editing therapies for cardiovascular diseases.迈向心血管疾病的基因组编辑治疗。
J Clin Invest. 2022 Jan 4;132(1). doi: 10.1172/JCI148555.
6
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.CRISPR-Cas9 体内基因编辑治疗转甲状腺素蛋白淀粉样变性。
N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
7
What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?我们从PCSK9抑制剂的ODYSSEY和FOURIER结果试验中对脂质与心血管风险有了哪些了解？
Cardiovasc Res. 2019 Mar 1;115(3):e26-e31. doi: 10.1093/cvr/cvy301.
8
Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population.比较五种主要指南在当代一般人群中的他汀类药物一级预防的应用。
Ann Intern Med. 2018 Jan 16;168(2):85-92. doi: 10.7326/M17-0681. Epub 2018 Jan 2.
9
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.不同治疗干预措施下降低低密度脂蛋白胆固醇（LDL-C）与心血管风险降低之间的关联：一项系统评价和荟萃分析
JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985.
10
Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo--brief report.在急性冠状动脉综合征患者中，氧化型低密度脂蛋白与循环血小板的结合增加，并在体内诱导血小板黏附于血管壁——简短报告。
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):2017-20. doi: 10.1161/ATVBAHA.111.244707. Epub 2012 Jun 14.
Zotero 插件